Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma

Trial Profile

A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Vorinostat (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top